Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease.

Article Details

Citation

Copy to clipboard

Berger W, De Chandt MT, Cairns CB

Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease.

Int J Clin Pract. 2007 Apr;61(4):663-76.

PubMed ID

17394438 [ View in PubMed

]

Abstract

The 5-Lipoxygenase pathway results in the formation of leukotrienes, including leukotriene B(4) (LTB(4)), 5-oxo-6E,8Z,11Z,14Z-eicosatetranoic acid and the cysteinyl leukotrienes (LTC(4), LTD(4) and LTE(4)) and activates all four leukotriene receptors, BLT1, BLT2, cysLT(1) and cysLT(2). Zileuton is the only commercially available inhibitor of the 5-Lipoxygenase pathway. In a number of clinical trials, zileuton has been shown to improve airway function and inflammation, asthma symptom control and quality of life in asthmatics. Given the important role that leukotrienes play in airway inflammation, zileuton provides an additional therapeutic option in the management of chronic, persistent asthma, particularly those asthmatics with more severe disease. In addition, zileuton has shown promise in a number of other conditions, including upper airway inflammatory conditions, dermatological disease and chronic obstructive pulmonary disease. The development of new formulations, including a controlled release tablet formulation for b.i.d. dosing and an intravenous preparation for acute asthma exacerbations may enhance clinical utility and expand therapeutic indications.

DrugBank Data that Cites this Article

Drugs

Zileuton

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Zileuton	Arachidonate 5-lipoxygenase	Protein	Humans	Yes	Inhibitor	Details